Products from BPS Bioscience require a minimum order value above 400€
Background: Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5, also known as CD66e) is a cell surface glycoprotein that serves as a cell adhesion protein. It has been used as a clinical biomarker to detect liver metastasis from gastrointestinal cancers and to predict gastrointestinal cancer relapse. CEACAM5 was recently identified as a potential target antigen for CAR T-cell therapy. Additionally, CEACAM5 may be involved in the inhibition of cell differentiation, apoptosis, and cell polarity.
CAS Number: 2254086-60-5
Description: Tusamitamab ravtansine (SAR-408701) is a targeted ADC against tumor cells expressing CEACAM5, composed of a humanized anti-CEACAM5 monoclonal antibody covalently linked to the potent cytotoxic agent, maytansinoid DM4 , via a cleavable linker. Tusamitamab ravtansine has an average drug-to-antibody ratio (DAR) of 3.81,2,3.
Format: Aqueous buffer solution.
Purity: ≥90%
Storage Stability: Store at -80°C, protect from light.
Target: CEACAM5
Uniprot: P06731
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: Not applicable (BSL-1)
References: 1. Lorenzo Belluomini, et al., 2023 Cancers (Basel) 15(22):5368. 2. Ye-Jin Kim, et al., 2023 Front Oncol. 13:1124039. 3. Gazzah A, et al., 2022 Ann Oncol. 33(4):416-425.
English
Deutsch
